AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00300391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: haloperidol
Description: Aim #1. To conduct a RCT of IV haloperidol vs. placebo for the treatment of delirium in mechanically ventilated ICU patients. Patients in the cohort study that go on to develop delirium will be enrolled in a RCT comparing treatment with scheduled haloperidol vs. placebo. By comparing differences between treatment and placebo groups, we will test the hypothesis that treatment with scheduled haloperidol improves the primary outcome of 28-day and 90 day mortality and secondary outcomes of total delirium days, duration of mechanical ventilation, and ICU length of stay.
Study NCT00300391 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: control arem
Study NCT03539081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry Scan
Description: Body composition analysis will be obtained by DEXA scan.
Study NCT03539081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dual-energy X-ray absorptiometry Scan
Description: Body composition analysis will be obtained by DEXA scan.
Study NCT03539081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Measurements
Description: The following labs will be obtained during the course of the study: pregnancy test (urine), glucose, insulin, catecholamine, and cholesterol (serum).
Study NCT03539081 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Laboratory Measurements
Description: The following labs will be obtained during the course of the study: pregnancy test (urine), glucose, insulin, catecholamine, and cholesterol (serum).
Study NCT03539081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Measurement
Description: The blood flow to the arm or leg may also be measured by placing an ultrasonic probe on the skin over the femoral artery of the leg and the brachial artery of the arm.
Study NCT03539081 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood Flow Measurement
Description: The blood flow to the arm or leg may also be measured by placing an ultrasonic probe on the skin over the femoral artery of the leg and the brachial artery of the arm.
Study NCT03539081 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Continuous Blood Pressure
Description: Continuous Blood pressure cuff will worn for 2 days with spinal cord stimulator on and off (24 hour on and 24 hour off). Optional procedure.
Study NCT03539081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partial pressure of oxygen
Description: Transcutaneous recordings will be captured to measure the partial pressure of oxygen by placing monitors on the subject's chest and foot.
Study NCT03539081 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Partial pressure of oxygen
Description: Transcutaneous recordings will be captured to measure the partial pressure of oxygen by placing monitors on the subject's chest and foot.
Study NCT03539081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microneurography
Description: The sympathetic nervous system activity to the subject's leg muscles will be measured by a tiny microelectrode placed in the peroneal nerve in the leg located just below the knee on the outer part of the leg. When the nerve is located 2 tiny sterile microelectrodes will be inserted through the skin.
Study NCT03539081 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Microneurography
Description: The sympathetic nervous system activity to the subject's leg muscles will be measured by a tiny microelectrode placed in the peroneal nerve in the leg located just below the knee on the outer part of the leg. When the nerve is located 2 tiny sterile microelectrodes will be inserted through the skin.
Study NCT03539081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anthropometric Measurements
Description: Height and weight will be obtained.
Study NCT03539081 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anthropometric Measurements
Description: Height and weight will be obtained.
Study NCT03539081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: John Hopkins Restless Legs Severity Scale
Description: Subjects will be administered questionnaires to evaluate RLS symptoms using John Hopkins Restless Legs Severity Scale.
Study NCT03539081 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Continuous Blood Pressure Diary
Description: Subjects participating in Continuous Blood Pressure monitoring will be administered continuous blood pressure monitoring compliance diary.
Study NCT02025621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Study NCT02025621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT01594281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: Pre-filled syringe for intravitreal injection
Study NCT01594281 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal laser photocoagulation
Description: PRP treatment following DRS guidelines
Study NCT01594281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal laser photocoagulation
Description: PRP treatment following DRS guidelines
Study NCT02397967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessments
Description: Neuropsychological assessments:~Intelligence Quotient (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette test, Lobrot test, Odedys test. Visio-spatial skill (JLO, Thurston, Corsi tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)
Study NCT02397967 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neuropsychological assessments
Description: Neuropsychological assessments:~Intelligence Quotient (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette test, Lobrot test, Odedys test. Visio-spatial skill (JLO, Thurston, Corsi tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)
Study NCT04253470 — intervention group
Intervention type: OTHER
Intervention: embryo transfer
Description: Step of the assisted reproduction in which embryos are placed into the uterus in order to obtain a pregnancy
Study NCT03961295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab SC
Description: Vedolizumab SC liquid.
Study NCT03961295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab SC liquid.
Study NCT01936272 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chhabra Shunt Placement
Study NCT01936272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ETV/CPC
Study NCT04319770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enamel matrix derivative (EMD)
Description: periodontal regenerative surgery with enamel matrix derivative (EMD) (control)
Study NCT04319770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyaluronic acid (HA)
Description: periodontal regenerative surgery with hyaluronic acid (HA) (test)
Study NCT04599972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSF-1
Description: One drop bilaterally twice daily for approximately 2 weeks.
Study NCT04599972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: One drop bilaterally twice daily for approximately 2 weeks.
Study NCT02907281 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational
Study NCT02597985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prehabilitation
Description: Supervised exercise training intervention will include three sessions per week for four weeks at a Mayo Clinic system cardiac rehabilitation facility. The Rochester, Minnesota Cardiac Rehabilitation Program will provide guidance and oversight. Modes of aerobic exercise will include treadmill walking (the primary mode of training) supplemented with non-weight-bearing activities such as stationary cycling and combination arm/leg recumbent exercise (NuStep device), as needed. Intensity will be set using Borg Perceived Exertion Scale (RPE) ratings of 12-14 (somewhat hard), keeping patients below the threshold for more than mild angina.
Study NCT02597985 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Study NCT00028795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT00028795 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00028795 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01149772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACCESS
Description: Participants received 6 treatment sessions (2 core and 4 electives). The two core modules are increasing awareness and controlling physical and emotional symptoms. After completion of the core modules the participant was able to choose elective modules from Managing Physical Health, The Power of Thoughts, Increasing Pleasant Activities, and Relaxation. Participants were required to complete the first session in person and subsequent sessions participants had the option to complete in-person or over the phone. Participants also had the option to receive 2 brief follow-up booster calls to aid in reinforcing the changes made.
Study NCT01659359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses and Lidocaine
Description: The samples were randomly allocated to use Virtual reality glasses and 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
Study NCT01659359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The samples were randomly allocated to use 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
Study NCT02505802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT-A injection
Description: In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu).
Study NCT00742040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril
Description: A rapid 3-day up-titration protocol
Study NCT00742040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Captopril
Description: A slower 9-day up-titration protocol
Study NCT00474006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arm II
Description: Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 90 mg/m2/d civ x 3 days
Study NCT00432640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound staging
Description: Endoscopic ultrasound staging with both EUS-FNA and EBUS-TBNA
Study NCT00432640 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical staging
Description: Surgical staging
Study NCT03718273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.~Patients with 75 or more years of age will receive an initial dose of 2.5 mg / twice a day, which can be increased to 5 mg / twice a day in week 7 and to 7.5 mg in month 1 if the tolerance has been good
Study NCT03718273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: The initial dose will be based on whether there are factors such as age over 80 years, weight less than 60 kg and creatinine clearance \<60ml / min, if there is no factor, the oral dose will be 0.25mg / 24h. If there are 2 factors, the dose will be 0.15 mg / 24 h. and if there are 2 or 3 factors, the dose will be 0.10 mg / 24 h.
Study NCT02801006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenfilcon A
Description: contact lens
Study NCT02801006 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: contact lens
Study NCT00552344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cimzia
Description: * Active substance: Certolizumab Pegol~* Pharmaceutical form:first reconstituted, lyophilized powder formulation of CZP and after implementation of Amendment 2 (after 401 subjects were enrolled) prefilled syringe~* Concentration: 200 mg/ml~* Route of Administration: Subcutaneous use
Study NCT03007628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magpro X100
Description: In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
Study NCT03007628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThymatronSystem Ⅳ Electroconvulsive System
Description: In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
Study NCT03007628 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Participants will engage in their intpatient treatment program as-usual.
Study NCT03007628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: Participants will engage in their intpatient treatment program as-usual.
Study NCT02253628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold espresso
Description: Volunteers consumed cold espresso with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
Study NCT02253628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot instant coffee
Description: Volunteers consumed hot instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
Study NCT02253628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold instant coffee
Description: Volunteers consumed cold instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
Study NCT02253628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot filter coffee
Description: Volunteers consumed hot filter coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
Study NCT00314054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCV-796
Description: HCV-796 1000mg single dose
Study NCT03592394 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Virtual Reality (Gear VR)
Description: Immersing the user in a total visual environment.
Study NCT00245349 — intervention group
Intervention type: PROCEDURE
Intervention: F-18 Fluorothymidine
Study NCT01975376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bococizumab (PF-04950615)
Description: 150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
Study NCT01975376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
Study NCT00003761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rV-DF3/MUC1
Description: - The starting dose for this Phase I study of rV-DF3/MUC1 will be 4.76 x 106 PFU.~-- Dose escalation will proceed with cohorts of at least 6 patients as follows: Per vaccination~* Level 1 4.76 x 106 PFU~* Level 2 4.76 x 107 PFU~* Level 3 4.76 x 108 PFU
Study NCT02111629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole and Secnidazole
Study NCT00904176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 20 mg, followed by 10 mg, Single Dose
Study NCT00904176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Tablets, Oral, 25 mg, Single Dose
Study NCT00904176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Tablets, Oral, 0.25, Single Dose
Study NCT04424004 — intervention group
Intervention type: OTHER
Intervention: COVID-19 PCR and serology testing
Description: 1. PCR testing: participate will conduct at-home collection and return of self-administered nasal swabs for COVID-19 polymerase chain reaction (PCR) viral testing. Saliva specimens may replace the nasal swab specimen. Specimens will be collected at baseline and every 2 weeks in conjunction with questionnaire administration.~2. Serology testing: The same randomized participants will also provide a blood sample for serologic testing for SARS-CoV-2 IgG antibodies. Specimens will be collected by routine venipuncture at the MURDOCK Study office in Kannapolis, NC.Specimens for serology will be collected at baseline approximately 1 month after the first questionnaire and 2 weeks after the first nasal swab collection and COVID-19 PCR testing. Specimens for serology will be collected at least bi-monthly and up to monthly thereafter through a total study duration of 6, and up to 12, months.
Study NCT00053222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Study NCT04516824 — intervention group
Intervention type: PROCEDURE
Intervention: Orthopaedic Surgical Procedures
Description: Intramedullary nails, Dynamic Compression Plate, Dynamic Hip Screw, Manipulation Under Anaesthesia POP, Ilizarov, Cannulated Screw Fixators, Bipolar Hemiarthroplasty, Locking Compression Plate, AO External fixators, Tension Band Wiring Patella, Pelvis and Acetabulum Fixations, Elbow Reconstructions, K wiring, Disc Excision, Spine Fracture i-e TPSF, Posterior Cervical Decompression and LMS, Dura repair, AD cage,Bilateral Total Hip Replacement, Unilateral Total Hip Replacement, Bilateral Total Knee Replacement, Unilateral Total Knee Replacement, Knee Arthroscopy for Mensicectomy, Arthroscopic Anterior Cruciate Ligament reconstruction,Removal of Implant, Amputations, VAC dressings,Wound wash, Arthrotomy for Septic Arthritis, Biopsy
Study NCT02870257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening protocol with progressive load
Description: Strengthening protocol for scapular and shoulder muscles
Study NCT02870257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening protocol without progressive load
Description: Strengthening protocol for scapular and shoulder muscles
Study NCT02855645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichosanthes root
Description: Trichosanthes root at a rate of 1.5 g two times per day for 84 days.
Study NCT02855645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Trichosanthes root at a rate of 0.15g (10%) two times per day for 84 days.
Study NCT01646567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP-141C
Description: Topical Cream
Study NCT01646567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to SHP-141C
Description: Placebo Topical Cream
Study NCT01646567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Valerate
Description: Topical cream, 0.02%
Study NCT01646567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol
Description: Topical cream, 0.005%
Study NCT01304472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel 10mg per day
Study NCT01304472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 150mg per day
Study NCT02125630 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery to primary tumor
Study NCT02125630 — intervention group
Intervention type: DRUG
Intervention: Systemic therapy
Description: Systemic therapy based on tumor phenotype
Study NCT01024660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 5 mg capsule, orally, once daily, first 14 days of treatment
Study NCT01024660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 10 mg, orally, once daily, for remaining 70 days of treatment
Study NCT01024660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Aricept
Description: Placebo capsule, orally, 84 days of treatment
Study NCT04509401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B 6 with Magnesium
Description: Patients of intervention group will receive high dose of vitamin B6 with magnesium. This group will receive high dose of vitamin B6 with magnesium orally for 12 weeks.
Study NCT04509401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of vitamin B6 and magnesium
Description: Patients of control group will receive oral placebo tablet in the same manner, schedule for 12 weeks.
Study NCT03158090 — intervention group
Intervention type: PROCEDURE
Intervention: Transnasal butterfly surgery
Description: The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient.
Study NCT03158090 — intervention group
Intervention type: DRUG
Intervention: sandostatin
Description: The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient